Figure 1

Sunitinib and Regorafenib inhibit mammary tumor cell migration. A scratch wound assay was performed on RJ345, RJ348, MCF-7 and MDA-MB-231 cells treated with 500 nM or 5 μM of Regorafenib, Sunitinib or Imatinib. (A-D) shows representative scratch wounds from RJ348 cells at time 0 (A,C) and 24 hrs (B,D) after the initiation of the scratch when the cells were treated with the vehicle control, DMSO (A,B), or 5 μM of Sunitinib (C,D). The red line indicates the initial scratch wound. The percentage of the wound closed was quantified from a minimum of 3 independent replicates and is expressed as mean ± SEM when treated with (E) 500 nM or (F) 5 μM of Regorafenib, Sunitinib or Imatinib. Wounds were created and inhibitors were added immediately. Wounds were evaluated at 24 hrs after inhibitor administration for the RJ348 cells and 48 hrs for RJ345, MCF-7 and MDA-MB-231 cells. *Indicates values that were significantly different (p < 0.05) from the DMSO control.